News / Taiwan / cnyes
AJ Biologics Files for Phase 3 Clinical Trial of SBMA Drug with US FDA
Health Technology · Biotechnology · cnyes · 2026-09-04
7754
AJ Biologics has submitted a Phase 3 clinical trial application to the FDA for its SBMA treatment, AJ201, aiming for a Q4 launch to bolster its global licensing potential.
What Happened
Clinical Progress: AJ Biologics (7754-TW) has officially submitted a Phase 3 pivotal trial application to the U.S. FDA for its core drug candidate, AJ201, designed to treat Spinal and Bulbar Muscular Atrophy (SBMA). Pending a standard 30-day FDA review period without requests for further information, the global clinical trial is expected to commence as early as the fourth quarter of this year.
Trial Strategy: The Phase 3 study aims to enroll 200 patients globally, with the timeline subject to adjustments based on international licensing partners' development strategies. AJ201 has already secured Orphan Drug Designation from both the FDA and EMA, along with Fast Track designation, with patent protection potentially extending until 2044.
Strategic Value: The company highlights that AJ201 is currently the only known drug candidate for SBMA to reach the Phase 3 clinical stage globally. This milestone significantly enhances the drug's market value and strengthens the company's negotiating position for future global licensing and partnership agreements.
Market Potential: Market research from L.E.K. Consulting indicates that there are over 12,000 SBMA patients worldwide. The potential annual market for this treatment is estimated to reach as high as $2.5 billion, underscoring the substantial commercial opportunity for this rare disease therapy.